Abstract
ABSTRACT Screening tests to identify fetuses at risk for aneuploidies should be offered to all pregnant women. It should be remembered that screening tests can not diagnose a birth defect; they can only indicate an increased risk. An abnormal screening test result simply mean that additional testing is recommended. Maternal serum biochemical markers in first trimester are free beta-hCG and PAPP-A. In second trimester the markers are AFP, UE3, hCG (Triple test) and inhibin added to these three markers forming the quadruple test. Level of cell free fetal DNA and fetal cells in maternal circulation are some of the molecular techniques for prenatal diagnosis of aneuploidies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Donald School Journal of Ultrasound in Obstetrics and Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
